Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17121928
Yoon P, et al. (2006) Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. Mol Cancer Ther 5, 2815-23 17121928
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T37-p - 4E-BP1 (human)
Modsite: PPGDysttPGGtLFs SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T37‑p, 4E‑BP1 (mouse): T36‑p, 4E‑BP1 (rat): T36‑p, 4E‑BP1 (fruit fly): T37‑p, 4E‑BP1 (cow): T37‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  BV-173 (myeloid), K562 (erythroid)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  KT-1 CML line
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
As2O3 increase
rapamycin As2O3 no change compared to control
LY294002 As2O3 inhibit treatment-induced increase

T46-p - 4E-BP1 (human)
Modsite: GGtLFsttPGGtRII SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T46‑p, 4E‑BP1 (mouse): T45‑p, 4E‑BP1 (rat): T45‑p, 4E‑BP1 (fruit fly): T46‑p, 4E‑BP1 (cow): T46‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  BV-173 (myeloid), K562 (erythroid)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  KT-1 CML line
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
As2O3 increase
rapamycin As2O3 no change compared to control
LY294002 As2O3 inhibit treatment-induced increase

T70-p - 4E-BP1 (human)
Modsite: rNsPVtktPPRDLPt SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T70‑p, 4E‑BP1 (mouse): T69‑p, 4E‑BP1 (rat): T69‑p, 4E‑BP1 (fruit fly): T70‑p, 4E‑BP1 (cow): T70‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  BV-173 (myeloid), K562 (erythroid)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  KT-1 CML line
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
As2O3 increase
rapamycin As2O3 inhibit treatment-induced increase
LY294002 As2O3 inhibit treatment-induced increase

S2448-p - mTOR (human)
Modsite: RsRtRtDsysAGQsV SwissProt Entrez-Gene
Orthologous residues
mTOR (human): S2448‑p, mTOR (mouse): S2448‑p, mTOR (rat): S2448‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  BV-173 (myeloid), K562 (erythroid)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  KT-1 CML line
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
As2O3 increase

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  BV-173 (myeloid), K562 (erythroid)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  KT-1 CML line

T444-p - p70S6K (human)
Modsite: RFIGsPRtPVsPVkF SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T444‑p, p70S6K iso2 (human): T421‑p, p70S6K (mouse): T444‑p, p70S6K (rat): T444‑p, p70S6K iso2 (rat): T421‑p, p70S6K (fruit fly): S429‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  BV-173 (myeloid), K562 (erythroid)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  KT-1 CML line
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
As2O3 increase
As2O3 increase
rapamycin As2O3 inhibit treatment-induced increase
LY294002 As2O3 inhibit treatment-induced increase

S447-p - p70S6K (human)
Modsite: GsPRtPVsPVkFsPG SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): S447‑p, p70S6K iso2 (human): S424‑p, p70S6K (mouse): S447‑p, p70S6K (rat): S447‑p, p70S6K iso2 (rat): S424‑p, p70S6K (fruit fly): S430‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  BV-173 (myeloid), K562 (erythroid)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  KT-1 CML line
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
As2O3 increase
As2O3 increase
rapamycin As2O3 inhibit treatment-induced increase
LY294002 As2O3 inhibit treatment-induced increase

S235-p - S6 (human)
Modsite: IAKRRRLssLRAsts SwissProt Entrez-Gene
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p, S6 (fruit fly): A234‑p, S6 (cow): S235‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  BV-173 (myeloid), K562 (erythroid)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  KT-1 CML line
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
As2O3 increase
rapamycin As2O3 inhibit treatment-induced increase
LY294002 As2O3 inhibit treatment-induced increase

S236-p - S6 (human)
Modsite: AKRRRLssLRAstsK SwissProt Entrez-Gene
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p, S6 (fruit fly): S235‑p, S6 (cow): S236‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  BV-173 (myeloid), K562 (erythroid)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  KT-1 CML line
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
As2O3 increase
rapamycin As2O3 inhibit treatment-induced increase
LY294002 As2O3 inhibit treatment-induced increase

S240-p - S6 (human)
Modsite: RLssLRAstsKsEss SwissProt Entrez-Gene
Orthologous residues
S6 (human): S240‑p, S6 (mouse): S240‑p, S6 (rat): S240‑p, S6 (fruit fly): S239‑p, S6 (cow): S240‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  BV-173 (myeloid), K562 (erythroid)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  KT-1 CML line
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
As2O3 increase
rapamycin As2O3 inhibit treatment-induced increase
LY294002 As2O3 inhibit treatment-induced increase

S244-p - S6 (human)
Modsite: LRAstsKsEssQK__ SwissProt Entrez-Gene
Orthologous residues
S6 (human): S244‑p, S6 (mouse): S244‑p, S6 (rat): S244‑p, S6 (fruit fly): V243‑p, S6 (cow): S244‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  BV-173 (myeloid), K562 (erythroid)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  KT-1 CML line
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
As2O3 increase
rapamycin As2O3 inhibit treatment-induced increase
LY294002 As2O3 inhibit treatment-induced increase